Need for vigilance amid new 'Nimbus' COVID variant – DW – 06/25/2025
A new Omicron subvariant has caused infections and deaths in South and Southeast Asia. Europe may see a spike after population immunity fell over the winter.
What you need to know
European health authorities are warning there may be an increase in COVID-19 infections in the coming months amid the spread of the new Omicron variant NB.1.8.1. or "Nimbus."
"We have — what feels like — a fairly standard suite of recommendations that are being repeated," Ajibola Omokanye, an ECDC respiratory viruses expert, told DW.
"But we remain watchful."
The 2024-2025 winter in the Northern Hemisphere has given experts like Omokanye good reason to be watchful.
Population immunity against SARS-CoV-2, the virus that causes COVID-19, is down in Europe, probably due to fewer COVID cases over the winter.
As a result, Omokanye said there may be an increase in infections over the European summer. That may include severe cases that require treatment in hospital.
To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video
SARS-CoV-2 is becoming more endemic in communities but it is "still not a season pathogen, like influenza," said Omokanye.
COVID still appears to move and mutate in unpredictable ways and that "stresses the need for continued vigilance and not being complacent about SARS-CoV-2,' said Omokanye.
"Just in the same way that we're not complacent about influenza or RSV."
Bangladesh has already seen deaths due to COVID in June. China and Singapore have also detected new cases of the respiratory disease.
Deaths in places like Bangladesh may be partly due to people's poor access to healthcare.
By comparison, Omokanye cited Canada, where Nimbus is dominant but without the same rates or severity of cases.
But it's not only a case of access to healthcare. "There are multiple factors. First, it's the timing of [a] variant's emergence," Omokanye said.
Another, he said, is that a there could be a greater possibility for waning immunity where there's been low circulation for a long period of time.
With vaccination, there are also several important factors: Which vaccines are available in each country or region and "who they are given to and when," said Omokanye.
"The question is: are the vaccines being taken up by that proportion of the population where you see the most severe disease?"
Similarly with healthcare systems and access to supportive treatment, because localized differences may determine how seriously infections progress in a population.
"They all contribute to the picture for severe disease," said Omokanye.
To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video
ECDC and the World Health Organization have classified Nimbus as a Variant under Monitoring (VOM) due to two specific spike mutations.
The spikes are the "prongs" that enable the virus to latch onto and infect human cells. They have regularly mutated since SARS-CoV-2 first emerged.
Spike protein mutations reduce the ability of human antibodies to neutralize an infection and others that enhance the virus' ability to evade human antibodies.
VOM is the lowest category in a system where the more severe stages are Variant of Interest and Variant of Concern.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
DW
9 hours ago
- DW
'Miracle' HIV drug lenacapavir approved amid US budget cuts – DW – 06/24/2025
The US has approved lenacapavir for HIV prevention. However, experts worry that cuts to the health budget will "squander" the drug's chance of reducing infections. The battle against HIV has been dealt repeated blows in 2025 with cuts to funding for major global aid programs by the United States. There have also been budget cuts closer to home. And experts have told DW the cuts risk undermining efforts to end the HIV epidemic in the US by 2030, even now, with the approval of lenacapavir — what UNAIDS officials have described as a "miracle" drug — in HIV prevention. Lencapavir provides six months of protection against HIV infection. The renowned journal named it 2024's scientific "breakthrough of the year." Some experts are asking whether the promise of the drug could be undone by the defunding of US public health agencies that are vital for getting lencapavir to those who need it most. "Are we going to squander this, probably the greatest opportunity in 44 years of HIV prevention both in the US and globally?" asked Mitchell Warren, executive director of the nonpartisan HIV organization AVAC, in an interview with DW. Winnie Byanyima, executive director of UNAIDS, the United Nations agency that addresses HIV and AIDS around the world, dubbed lenacapavir a "miracle product" in 2024. If it was hype, it was well-founded hype. In late-stage clinical trials, lenacapavir had a near-perfect record of suppressing HIV infection. Having already approved it as a treatment to reduce viral load in patients with the disease, the US Food and Drug Administration has now confirmed lenacapavir as a pre-exposure prophylaxis (PrEP) drug. PrEP drugs are taken before having unprotected sex or injecting drugs to protect against HIV. Unlike other PrEP drugs, which aim to disrupt the virus at one stage of its life cycle, lencapavir has been shown to attack HIV at several stages, increasing its effectiveness. About 400,000 US patients use some form of PrEP, usually a daily pill. But a twice-a-year injection with lenacapavir would provide people with the longest-lasting protection yet. To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video In his first term, US President Donald Trump started an "Ending the HIV Epidemic" (EHE) initiative, an effort to stop the transmission of the disease within the US by the end of this decade. But the current Trump administration's cost-cutting drive has downsized the federal health budget, affecting key public health agencies, such as the National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC), and programs including Medicare and Medicaid. America's global aid initiatives, including USAID and PEPFAR (the President's Emergency Plan for AIDS Relief), have also been substantially wound back. "Whether it's the NIH research infrastructure [or] USAID for foreign assistance, these are big programs and none of them are HIV specific," Warren said. "But each one of them is diminished now in [its ability] to deliver the comprehensive and integrated programs that have been really at the forefront [of HIV response]." The result of this lost funding, Warren said, is that especially vulnerable groups, such as those from low-income backgrounds, gay and bisexual men and sex workers, may not benefit from the new PrEP drug, lenacapavir, which could provide them with unprecedented protection. Research has found that in US states which have expanded Medicaid coverage to offer health services to "all people with household incomes below a certain level," a growing number of people are using PrEP. Jeffrey Crowley, director of the Center for HIV and Infectious Disease Policy at the O'Neill Institute in Washington, said services like expanded Medicaid coverage have meant better access to HIV programs for those with the disease. "This is an incredible accomplishment, and it's helped drive a lot of the progress we've seen," Crowley told DW. He also said the cuts will mean people lose access to HIV services, which other programs can't cover. "I think the American people can be proud of how we responded to the HIV crisis domestically and globally, but this is all at risk. We've come so far, after so much death, why would we take a step backward?" To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video Every year, more than a million new HIV cases are reported globally and, until recently, US support through programs like USAID and PEPFAR was essential in helping regions most affected by the disease, especially countries in Africa. However, the Trump administration's aid withdrawal has already had an impact. Data from UNAIDS suggests there will be 2,300 more HIV cases per year because of the cuts to PEPFAR alone. Annual infections to date were already at about 3,500. "Less funding means we will get more and more off track," said Byanyima in mid-June. "We don't know what the total impact [of the US cuts] will be, but impact there will be. Already, you see in several countries a drop in the number of people going to clinics." The US government continues to support pregnant women and new mothers via PEPFAR, but the changes have stopped access to PrEP for gay and bisexual men, sex workers and drug users — groups that are disproportionately affected by HIV. Warren said it was akin to "throwing out a whole generation" of progress.
DW
10 hours ago
- DW
Need for vigilance amid new 'Nimbus' COVID variant – DW – 06/25/2025
A new Omicron subvariant has caused infections and deaths in South and Southeast Asia. Europe may see a spike after population immunity fell over the winter. What you need to know European health authorities are warning there may be an increase in COVID-19 infections in the coming months amid the spread of the new Omicron variant NB.1.8.1. or "Nimbus." "We have — what feels like — a fairly standard suite of recommendations that are being repeated," Ajibola Omokanye, an ECDC respiratory viruses expert, told DW. "But we remain watchful." The 2024-2025 winter in the Northern Hemisphere has given experts like Omokanye good reason to be watchful. Population immunity against SARS-CoV-2, the virus that causes COVID-19, is down in Europe, probably due to fewer COVID cases over the winter. As a result, Omokanye said there may be an increase in infections over the European summer. That may include severe cases that require treatment in hospital. To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video SARS-CoV-2 is becoming more endemic in communities but it is "still not a season pathogen, like influenza," said Omokanye. COVID still appears to move and mutate in unpredictable ways and that "stresses the need for continued vigilance and not being complacent about SARS-CoV-2,' said Omokanye. "Just in the same way that we're not complacent about influenza or RSV." Bangladesh has already seen deaths due to COVID in June. China and Singapore have also detected new cases of the respiratory disease. Deaths in places like Bangladesh may be partly due to people's poor access to healthcare. By comparison, Omokanye cited Canada, where Nimbus is dominant but without the same rates or severity of cases. But it's not only a case of access to healthcare. "There are multiple factors. First, it's the timing of [a] variant's emergence," Omokanye said. Another, he said, is that a there could be a greater possibility for waning immunity where there's been low circulation for a long period of time. With vaccination, there are also several important factors: Which vaccines are available in each country or region and "who they are given to and when," said Omokanye. "The question is: are the vaccines being taken up by that proportion of the population where you see the most severe disease?" Similarly with healthcare systems and access to supportive treatment, because localized differences may determine how seriously infections progress in a population. "They all contribute to the picture for severe disease," said Omokanye. To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video ECDC and the World Health Organization have classified Nimbus as a Variant under Monitoring (VOM) due to two specific spike mutations. The spikes are the "prongs" that enable the virus to latch onto and infect human cells. They have regularly mutated since SARS-CoV-2 first emerged. Spike protein mutations reduce the ability of human antibodies to neutralize an infection and others that enhance the virus' ability to evade human antibodies. VOM is the lowest category in a system where the more severe stages are Variant of Interest and Variant of Concern.
Int'l Business Times
a day ago
- Int'l Business Times
Child Vaccine Coverage Faltering, Threatening Millions: Study
Efforts to vaccinate children against deadly diseases are faltering across the world due to economic inequality, Covid-era disruptions and misinformation, putting millions of lives at risk, research warned Wednesday. These trends all increase the threat of future outbreaks of preventable diseases, the researchers said, while sweeping foreign aid cuts threaten previous progress in vaccinating the world's children. A new study published in The Lancet journal looked at childhood vaccination rates across 204 countries and territories. It was not all bad news. An immunisation programme by the World Health Organization was estimated to have saved an estimated 154 million lives over the last 50 years. And vaccination coverage against diseases such as diphtheria, tetanus, whooping cough, measles, polio and tuberculosis doubled between 1980 and 2023, the international team of researchers found. However the gains slowed in the 2010s, when measles vaccinations decreased in around half of the countries, with the largest drop in Latin America. Meanwhile in more than half of all high-income countries there were declines in coverage for at least one vaccine dose. Then the Covid-19 pandemic struck. Routine vaccination services were hugely disrupted during lockdowns and other measures, resulting in nearly 13 million extra children who never received any vaccine dose between 2020 to 2023, the study said. This disparity endured, particularly in poorer countries. In 2023, more than half of the world's 15.7 million completely unvaccinated children lived in just eight countries, the majority in sub-Saharan Africa, according to the study. In the European Union, 10 times more measles cases were recorded last year compared to 2023. In the United States, a measles outbreak surged past 1,000 cases across 30 states last month, which is already more than were recorded in all of 2024. Cases of polio, long eradicated in many areas thanks to vaccination, have been rising in Pakistan and Afghanistan, while Papua New Guinea is currently enduring a polio outbreak. "Routine childhood vaccinations are among the most powerful and cost-effective public health interventions available," said senior study author Jonathan Mosser of the US-based Institute for Health Metrics and Evaluation (IHME). "But persistent global inequalities, challenges from the Covid pandemic, and the growth of vaccine misinformation and hesitancy have all contributed to faltering immunisation progress," he said in a statement. In addition, there are "rising numbers of displaced people and growing disparities due to armed conflict, political volatility, economic uncertainty, climate crises," added lead study author Emily Haeuser, also from the IHME. The researchers warned the setbacks could threaten the WHO's goal of having 90 percent of the world's children and adolescents receive essential vaccines by 2030. The WHO also aims to halve the number of children who have received no vaccine doses by 2030 compared to 2019 levels. Just 18 countries have achieved this so far, according to the study, which was funded by the Gates Foundation and the Gavi vaccine alliance. The global health community has also been reeling since President Donald Trump's administration drastically slashed US international aid earlier this year. "For the first time in decades, the number of kids dying around the world will likely go up this year instead of down because of massive cuts to foreign aid," Bill Gates said in a separate statement on Tuesday. "That is a tragedy," the Microsoft co-founder said, committing $1.6 billion to Gavi, which is holding a fund-raising summit in Brussels on Wednesday.
